Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels

Nature Communications

Volumn 4, Issue , 2013, Pages

  Chauhan, Vikash P ^a,b   Martin, John D ^a,c   Liu, Hao ^a,d   Lacorre, Delphine A ^a   Jain, Saloni R ^a,c   Kozin, Sergey V ^a   Stylianopoulos, Triantafyllos ^a,e   Mousa, Ahmed S ^a   Han, Xiaoxing ^a   Adstamongkonkul, Pichet ^a,b   Popović, Zoran ^f   Huang, Peigen ^a   Bawendi, Moungi G ^f   Boucher, Yves ^a   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF CYPRUS   (Cyprus)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR; CANDESARTAN; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; DOXORUBICIN; FLUOROURACIL; HYALURONIC ACID; LISINOPRIL; LOSARTAN; OXYGEN; TRANSFORMING GROWTH FACTOR BETA1; VALSARTAN;

BLOOD; CHEMOTHERAPY; COLLAGEN; DISEASE TREATMENT; DRUG DEVELOPMENT; HYPOXIA; OXYGEN; SWELLING; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DECOMPRESSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; HYPOXIA; INHIBITION KINETICS; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PERFUSION; PROTEIN EXPRESSION; STRESS; VASCULAR TUMOR;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSINS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; DRUG REPOSITIONING; DRUG SYNERGISM; ENDOTHELIN-1; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYALURONIC ACID; LOSARTAN; MAMMARY NEOPLASMS, EXPERIMENTAL; MECHANOTRANSDUCTION, CELLULAR; MICE; PANCREATIC NEOPLASMS; RECEPTOR, ANGIOTENSIN, TYPE 1; STRESS, MECHANICAL; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84885129359     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3516     Document Type: Article

References (63)

1. Chauhan, V. P., Stylianopoulos, T., Boucher, Y. & Jain, R. K. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Ann. Rev. Chem. Biomol. Eng. 2, 281-298 (2011).
2. Tsai, A. G., Johnson, P. C. & Intaglietta, M. Oxygen gradients in the microcirculation. Physiol. Rev. 83, 933-963 (2003). (Pubitemid 36828928)
3. Jain, R. K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol. 31, 2205-2218 (2013).
4. Helmlinger, G., Netti, P. A., Lichtenbeld, H. C., Melder, R. J. & Jain, R. K. Solid stress inhibits the growth of multicellular tumor spheroids. Nat. Biotechnol. 15, 778-783 (1997). (Pubitemid 27329482)
5. Stylianopoulos, T. et al. Causes, consequences, and remedies for growthinduced solid stress in murine and human tumors. Proc. Natl Acad. Sci. USA 109, 15101-15108 (2012).
6. Stylianopoulos, T. et al. Coevolution of solid stress and interstitial fluid pressure in tumors during progression: Implications for vascular collapse. Cancer Res. 73, 3833-3841 (2013).
7. Janmey, P. A. & McCulloch, C. A. Cell mechanics: integrating cell responses to mechanical stimuli. Annu. Rev. Biomed. Eng. 9, 1-34 (2007). (Pubitemid 350252899)
8. Griffon-Etienne, G., Boucher, Y., Brekken, C., Suit, H. D. & Jain, R. K. Taxaneinduced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res. 59, 3776-3782 (1999). (Pubitemid 29381886)
9. Padera, T. P. et al. Pathology: cancer cells compress intratumour vessels. Nature 427, 695 (2004). (Pubitemid 38294577)
10. Park, M. S. et al. Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo-and radiation therapy. Radiology 250, 110-117 (2009).
11. Sorensen, A. G. et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 72, 402-407 (2012).
12. Provenzano, Paolo P. et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418-429 (2012).
13. Alexandrakis, G. et al. Two-photon fluorescence correlation microscopy reveals the two-phase nature of transport in tumors. Nat. Med. 10, 203-207 (2004). (Pubitemid 38524893)
14. Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y. & Jain, R. K. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl Acad. Sci. USA 108, 2909-2914 (2011).
15. Liu, J. et al. TGF-b blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc. Natl Acad. Sci. USA 109, 16618-16623 (2012).
16. Naito, T. et al. Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-b1. Am. J. Physiol. 286, F278-F287 (2004). (Pubitemid 38141671)
17. Habashi, J. P. et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312, 117-121 (2006).
18. Sweetwyne, M. T. & Murphy-Ullrich, J. E. Thrombospondin1 in tissue repair and fibrosis: TGF-beta-dependent and independent mechanisms. Matrix Biol. 31, 178-186 (2012).
19. Liao, S. et al. Impaired lymphatic contraction associated with immunosuppression. Proc. Natl Acad. Sci. USA 108, 18784-18789 (2011).
20. Mori, T. et al. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model. J. Cell Physiol. 181, 153-159 (1999). (Pubitemid 29400382)
21. Duncan, M. R. et al. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: downregulation by cAMP. FASEB J. 13, 1774-1786 (1999). (Pubitemid 29473339)
22. Rodriguez-Vita, J. et al. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 111, 2509-2517 (2005). (Pubitemid 40696140)
23. Yang, F., Chung, A. C., Huang, X. R. & Lan, H. Y. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and-independent Smad pathways: the role of Smad3. Hypertension 54, 877-884 (2009).
24. Hama, K. et al. Angiotensin II stimulates DNA synthesis of rat pancreatic stellate cells by activating ERK through EGF receptor transactivation. Biochem. Biophys. Res. Commun. 315, 905-911 (2004). (Pubitemid 38249389)
25. Liu, W. B.,Wang, X. P.,Wu, K. & Zhang, R. L. Effects of angiotensin II receptor antagonist, Losartan on the apoptosis, proliferation and migration of the human pancreatic stellate cells. World J. Gastroenterol. 11, 6489-6494 (2005). (Pubitemid 43136886)
26. Leask, A. Targeting the TGF beta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. Cell Signal. 20, 1409-1414 (2008).
27. Shi-Wen, X. et al. Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Mol. Cell Biol. 26, 5518-5527 (2006). (Pubitemid 44036217)
28. Cheng, T. H. et al. Involvement of reactive oxygen species in angiotensin IIinduced endothelin-1 gene expression in rat cardiac fibroblasts. J. Am. Coll. Cardiol. 42, 1845-1854 (2003).
29. Habashi, J. P. H. J. P. et al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 332, 361-365 (2011).
30. Ulmasov, B., Xu, Z., Tetri, L. H., Inagami, T. & Neuschwander-Tetri, B. A. Protective role of angiotensin II type 2 receptor signaling in a mouse model of pancreatic fibrosis. Am. J. Physiol. Gastroint. Liver Physiol. 296, G284-G294 (2009).
31. Nabeshima, Y. et al. Anti-fibrogenic function of angiotensin II type 2 receptor in CCl4-induced liver fibrosis. Biochem. Biophys. Res. Commun. 346, 658-664 (2006).
32. George, A. J., Thomas, W. G. & Hannan, R. D. The renin-angiotensin system and cancer: old dog, new tricks. Nat. Rev. Cancer 10, 745-759 (2010).
33. Chauhan, V. P. et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol. 7, 383-388 (2012).
34. Baish, J. W. et al. Scaling rules for diffusive drug delivery in tumor and normal tissues. Proc. Natl Acad. Sci. USA 108, 1799-1803 (2011).
35. Helmlinger, G., Yuan, F., Dellian, M. & Jain, R. K. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med. 3, 177-182 (1997). (Pubitemid 27064702)
36. Arnold, S. A. et al. Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFb activation. PLoS One 7, e31384 (2012).
37. Rodrigues-Ferreira, S. et al. Angiotensin II facilitates breast cancer cell migration and metastasis. PLoS One 7, e35667 (2012).
38. Amano, H. et al. Angiotensin II type 1A receptor signaling facilitates tumor metastasis formation through P-selectin-mediated interaction of tumor cells with platelets and endothelial cells. Am. J. Pathol. 182, 553-564 (2013).
39. DeNardo, D. G. et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1, 54-67 (2011).
40. Pluen, A. et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc. Natl Acad. Sci. USA 98, 4628-4633 (2001). (Pubitemid 32295027)
41. Keizman, D. et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. Eur. J. Cancer 47, 1955-1961 (2011).
42. Nakai, Y. et al. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br. J. Cancer 103, 1644-1648 (2010).
43. Wilop, S. et al. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J. Cancer Res. Clin. Oncol. 135, 1429-1435 (2009).
44. Chae, Y. K. et al. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest. 29, 585-593 (2011).
45. Fujita, M. et al. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 26, 271-279 (2005). (Pubitemid 40253497)
46. Suganuma, T. et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin. Cancer Res. 11, 2686-2694 (2005). (Pubitemid 40569470)
47. Yoshiji, H. et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: Possible role of the vascular endothelial growth factor. Clin. Cancer Res. 7, 1073-1078 (2001). (Pubitemid 32708747)
48. Greco, S. et al. Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J. Cell Physiol. 196, 370-377 (2003). (Pubitemid 36775885)
49. Egami, K. et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J. Clin. Invest. 112, 67-75 (2003). (Pubitemid 38056377)
50. Doi, C. et al. Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice. BMC Cancer 10, 67 (2010).
51. Rhodes, D. R. et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc. Natl Acad. Sci. USA 106, 10284-10289 (2009).
52. Noguchi, R. et al. Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via antiangiogenic activities. Oncol. Rep. 22, 355-360 (2009).
53. Cook, K. L., Metheny-Barlow, L. J., Tallant, E. A. & Gallagher, P. E. Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors. Cancer Res. 70, 8319-8328 (2010).
54. Nakai, Y. et al. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Invest. N. Drugs. doi:10.1007/s10637-013-9972-5, (2013).
55. Michel, M. C., Foster, C., Brunner, H. R. & Liu, L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol. Rev. 65, 809-848 (2013).
56. Bardeesy, N. et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc. Natl Acad. Sci. USA 103, 5947-5952 (2006).
57. Sugaya, T. et al. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J. Biol. Chem. 270, 18719-18722 (1995).
58. Ichiki, T. et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 377, 748-750 (1995).
59. Motoike, T. et al. Universal GFP reporter for the study of vascular development. Genesis 28, 75-81 (2000).
60. Brown, E. B. et al. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat. Med. 7, 864-868 (2001). (Pubitemid 32691644)
61. Vakoc, B. J. et al. Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat. Med. 15, 1219-1223 (2009).
62. Chauhan, V. P. et al. Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew. Chem. Int. Ed. 50, 11417-11420 (2011).
63. Kamoun, W. S. et al. Simultaneous measurement of RBC velocity, flux, hematocrit and shear rate in vascular networks. Nat. Methods 7, 655-660 (2010).